BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 19011754)

  • 21. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
    Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
    Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 23. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinase inhibitor conjugates.
    Harmsen S; Kok RJ
    Curr Pharm Des; 2012; 18(20):2891-900. PubMed ID: 22571658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibitors of protein kinases in cancer- how to overcome resistance.
    Griffith R; Brown MN; McCluskey A; Ashman LK
    Mini Rev Med Chem; 2006 Oct; 6(10):1101-10. PubMed ID: 17073710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten things you should know about protein kinases: IUPHAR Review 14.
    Fabbro D; Cowan-Jacob SW; Moebitz H
    Br J Pharmacol; 2015 Jun; 172(11):2675-700. PubMed ID: 25630872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
    Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR inhibitors in the treatment of cancer.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1717-34. PubMed ID: 18922108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin.
    Kotecki N; Penel N
    Curr Opin Oncol; 2016 Sep; 28(5):437-40. PubMed ID: 27428364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
    Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
    Hantschel O
    ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting cancer with small molecule kinase inhibitors.
    Zhang J; Yang PL; Gray NS
    Nat Rev Cancer; 2009 Jan; 9(1):28-39. PubMed ID: 19104514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
    Sun GC; Yang X; Yu Y; Zhao DW
    Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
    Bortolato A; Cozza G; Moro S
    Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ALK gene, an attractive target for inhibitor development.
    Tartari CJ; Scapozza L; Gambacorti-Passerini C
    Curr Top Med Chem; 2011; 11(11):1406-19. PubMed ID: 21513493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.